Summarized by Masters of Longevity from Longevity Technology.
Report on a startup training large AI models on massive cross-species biological data to design broad regenerative therapies and in vivo cell reprogramming.
Key Takeaways
- Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.
- Most AI drug-discovery companies train their models on the small slice of biology that’s already been studied to death: human genomes, known disease pathways, existing drug compounds.
- Basecamp Research is betting on something closer to the opposite.
